Browsing Tag

Nasdaq:LABP

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of…

Eli Pacheco Oct 11, 2021 0

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late…

Health

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical…

Eli Pacheco Oct 6, 2021 0

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to…

Health

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation…

Eli Pacheco Jun 15, 2021 0

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to…

Health

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA…

Eli Pacheco Jun 14, 2021 0

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial…